Organisers: Stefanie Biedermann (Southampton), Vladimir Dragalin (Quintiles, USA), Sandra Eldridge (QMUL), Heiko Grossmann (QMUL), Michael Krams (Johnson & Johnson, USA) and Peter Mueller (Texas at Austin).
The purpose of this workshop is to gather together people working in various aspects of design of experiments in health-care, in the widest understanding of that word, from drug development in pre-clinical and clinical trials, treatment individualization, studies on primary care, and gathering evidence for public policy, to choice experiments in health economics. Participants and speakers include experts from industry and academia. Several talks will specifically focus on challenges and problems arising with the practical implementation of proposed strategies. Presentations describing both the current attempts to use DoE to overcome the recognized inefficiencies of the traditional drug development as well as the new challenges in implementing the DoE in clinical trials will be a basis for exchange of information among the researchers from the pharmaceutical companies, regulatory authorities, and from academia.
Presentations will be organized in sessions around the following themes:
- Treatment individualization
- Cluster randomized trials
- Step wedge designs
- Adaptive dose ranging study
- Choice experiments in health economics
- Designs for drug development
- Biomarkers and covariate adaptive designs
- Early phase model based design